As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
HOME > REGULATORY
REGULATORY
- Newly Sworn In Chief Gives “4 First” Pep Talk to PMDA Staffers
May 14, 2019
- Kymriah Likely to Fetch 33 Million Yen Price Tag, Collategene to Skip Listing
May 14, 2019
- Xofluza, Opdivo, Keytruda, Bavencio under PMDA Risk Review
May 13, 2019
- Pituitary Dysfunction Added to Significant Adverse Reaction for Opdivo: MHLW
May 10, 2019
- MHLW Launches Survey on Authorized Generics to Get Data for Chuikyo Debate
May 8, 2019
- Next Public-Private Confab Set for May 20 before Full-Swing Pricing Debate
May 8, 2019
- Entyvio’s Crohn’s Disease Indication in Line for Approval in May
May 7, 2019
- Chuikyo Agrees to Require Genetic Info Submission for Insurance Coverage of Cancer Genomic Panel Tests
April 25, 2019
- PMDA to Set Up New Consultation Services for RWD Use in Regulatory Submissions
April 24, 2019
- MOF Pitches Higher Copay for Pricey Drugs Deemed Not Cost Effective
April 23, 2019
- Lilly’s EGFR Antagonist, Japan’s 1st Avastin Biosimilar Now in Line for June Approval
April 22, 2019
- CEA Use in Reimbursement Decisions Our Ultimate Goal: MOF Budget Examiner
April 19, 2019
- Japan Drug Production Up 1.5% to 6.7 Trillion Yen in 2017: MHLW Survey
April 18, 2019
- LDP Junior Lawmakers to Launch Vaccine Study Group
April 17, 2019
- Entyvio’s Crohn’s Disease Use on Agenda for April 26 MHLW Panel Meeting
April 15, 2019
- CEFP Kicks Off Discussions towards 2020 Reimbursement Policy Reform
April 11, 2019
- Dupixent to Join Self-Injectable Drug List
April 11, 2019
- Supply of MSD’s Hep B Vaccine Heptavax Might Be Suspended as Early as October: MHLW
April 10, 2019
- MHLW Informally Notifies Drug Makers of Post-Oct. 1 NHI Prices
April 9, 2019
- Sakigake Status Granted to Takeda’s Narcolepsy Med, Ninlaro, Daiichi Sankyo’s Valemetostat and More
April 9, 2019
ページ
While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…